*MET* mutations and *MET* amplifications are reported in 1-6% of patients with non–small cell lung cancer (NSCLC). In the ongoing, multicohort phase 2 GEOMETRY trial, patients with stage III/IV NSCLC and high-level *MET* amplification (gene copy number >10) responded well to capmatinib, a highly potent and selective inhibitor of the MET receptor tyrosine kinase.
In the GEOMETRY trial, 84 patients with high-level *MET* amplification (*ALK* and *EGFR* wildtype, stage IIIB/IV) received capmatinib 400 mg twice daily (n=15 were treatment-naïve, n=69 were second or third line). The primary endpoint of the trial was the objective response rate (ORR), while secondary endpoints were duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
“The ORR in the treatment-naïve patients was 40%, and 29% in the pre-treated patients”, reported Prof. Jürgen Wolf (University Hospital Cologne, Germany) . “In the majority of patients thes...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Tiragolumab and atezolizumab: ORR in NSCLC Next Article
Urothelial cancer: avelumab works as maintenance therapy »
Table of Contents: ASCO 2020
COVID-19 & Telemedicine
Breast & Ovarian Cancer
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.